Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. [electronic resource]
Producer: 20130604Description: 823-8 p. digitalISSN:- 1476-5551
- Adult
- Aged
- Amyloidosis -- drug therapy
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Dexamethasone -- administration & dosage
- Female
- Humans
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Pyrazines -- administration & dosage
- Stem Cell Transplantation
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.